论文部分内容阅读
作者将液体白喉-破伤风-无细胞百日咳菌苗-脊髓灰质炎灭活疫苗（DTaP-IPV）和冻干b型流感杆菌（Hib）结合菌苗混合制成五价DTaP-IPV/Act-HIB联合疫苗。每0.5ml疫苗含白喉类毒素（DT）≥30IU、破伤风类毒素（TT）≥40IU、戊二醛灭活的百日咳类毒素（PT）25μg、天然丝状血凝素（FHA）25μg以及1、2、3型脊髓灰质炎病毒40、8、32D抗原单位、与24μg纯化TT结合的Hib荚膜多糖10μg。按2、4、6月龄初免、13月加强免疫或3、5月龄初免、12月龄加强免疫的程序,对236名婴儿进行免疫,于每次接种后3日内记录各类不良反应,并于初免后、加强免疫前后采血。用ELISA检测抗DT、TT抗体以及抗PT、FHA抗体;用中和试验（NT）检测抗各型脊髓灰质炎病毒抗体;用放射免疫法检测抗Hib荚膜多糖抗体。同时用NT检测抗DT抗体和抗PT抗体。
The authors prepared the pentavalent DTaP-IPV / Act-HIB by mixing the diphtheria-tetanus-acellular pertussis vaccine-poliomyelitis inactivated vaccine (DTaP-IPV) and the lyophilized bib model Hib vaccine Combined vaccine. Diphtheria toxoid (DT) ≧ 30 IU, tetanus toxoid (TT) ≧ 40 IU per gram of vaccine, 25 μg of glutaraldehyde inactivated pertussis toxoid (PT), 25 μg of native filamentous hemagglutinin (FHA) 10 μg of Hib capsular polysaccharide bound to 24 μg of purified TT, poliovirus type 3, 40, 8, 32D antigen units. Thirty-six infants were immunized at the initial stage of 2, 4 and 6 months, the intensive immunization in March or the initial immunization of 3 and 5 months and the 12-month intensive immunization. All infants were recorded within 3 days after inoculation Reaction, and after the initial exemption, to strengthen the blood before and after immunization. Anti-DT, TT and anti-PT, FHA antibodies were detected by ELISA. Anti-poliovirus antibodies were detected by neutralization assay (NT). Anti-Hib capsular polysaccharide antibodies were detected by radioimmunoassay. Anti-DT and anti-PT antibodies were also detected with NT.